443 related articles for article (PubMed ID: 23915749)
41. Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia.
Chan TS; Au-Yeung R; Chim CS; Wong SC; Kwong YL
Ann Hematol; 2017 May; 96(5):871-872. PubMed ID: 28184982
[No Abstract] [Full Text] [Related]
42. Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
Zhang SQ; Smith SM; Zhang SY; Lynn Wang Y
Br J Haematol; 2015 Aug; 170(4):445-56. PubMed ID: 25858358
[TBL] [Abstract][Full Text] [Related]
43. LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
Liu W; Burger JA; Xu J; Tang Z; Toruner G; Khanlari M; Medeiros LJ; Tang G
Ann Hematol; 2020 Oct; 99(10):2343-2349. PubMed ID: 32833105
[TBL] [Abstract][Full Text] [Related]
44. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
[TBL] [Abstract][Full Text] [Related]
45. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
Molica S; Gianfelici V; Levato L
Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
[No Abstract] [Full Text] [Related]
46. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Thompson PA; Burger JA
Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
[TBL] [Abstract][Full Text] [Related]
47. Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
Cervantes-Gomez F; Kumar Patel V; Bose P; Keating MJ; Gandhi V
Leukemia; 2016 Aug; 30(8):1803-4. PubMed ID: 27198052
[No Abstract] [Full Text] [Related]
48. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach.
Sivina M; Kreitman RJ; Arons E; Ravandi F; Burger JA
Br J Haematol; 2014 Jul; 166(2):177-88. PubMed ID: 24697238
[TBL] [Abstract][Full Text] [Related]
49. Ibrutinib for treatment of chronic lymphocytic leukemia.
Vela CM; McBride A; Jaglowski SM; Andritsos LA
Am J Health Syst Pharm; 2016 Mar; 73(6):367-75. PubMed ID: 26953281
[TBL] [Abstract][Full Text] [Related]
50. The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.
Herman SEM; Montraveta A; Niemann CU; Mora-Jensen H; Gulrajani M; Krantz F; Mantel R; Smith LL; McClanahan F; Harrington BK; Colomer D; Covey T; Byrd JC; Izumi R; Kaptein A; Ulrich R; Johnson AJ; Lannutti BJ; Wiestner A; Woyach JA
Clin Cancer Res; 2017 Jun; 23(11):2831-2841. PubMed ID: 27903679
[No Abstract] [Full Text] [Related]
51. Ibrutinib in B lymphoid malignancies.
Smith MR
Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
[TBL] [Abstract][Full Text] [Related]
52. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
Wodarz D; Garg N; Komarova NL; Benjamini O; Keating MJ; Wierda WG; Kantarjian H; James D; O'Brien S; Burger JA
Blood; 2014 Jun; 123(26):4132-5. PubMed ID: 24829205
[TBL] [Abstract][Full Text] [Related]
53. Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017.
Molica S
BMC Med; 2017 Aug; 15(1):156. PubMed ID: 28810856
[TBL] [Abstract][Full Text] [Related]
54. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
55. [Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].
Wang M; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):245-9. PubMed ID: 24598688
[TBL] [Abstract][Full Text] [Related]
56. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
[TBL] [Abstract][Full Text] [Related]
57. Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
Barrientos JC; Burger JA; Byrd JC; Hillmen P; Zhou C; Ninomoto J; James DF; Kipps TJ
Leuk Lymphoma; 2019 Apr; 60(4):1000-1005. PubMed ID: 30277101
[TBL] [Abstract][Full Text] [Related]
58. A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.
Lee CS; Rattu MA; Kim SS
J Oncol Pharm Pract; 2016 Feb; 22(1):92-104. PubMed ID: 25425007
[TBL] [Abstract][Full Text] [Related]
59. Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia.
Lee A; Sandhu S; Imlay-Gillespie L; Mulligan S; Shumack S
Australas J Dermatol; 2017 Nov; 58(4):e240-e242. PubMed ID: 28295171
[TBL] [Abstract][Full Text] [Related]
60. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
